Exton, Pennsylvania-based West Pharmaceutical Services, Inc. (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products. Valued at $25.7 billion by market cap, the company’s technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services. The leading manufacturer of containment and delivery systems is expected to announce its fiscal third-quarter earnings for 2026 in the near term.
Ahead of the event, analysts expect WST to report a profit of $2.18 per share on a diluted basis, up 11.2% from $1.96 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
For the full year, analysts expect WST to report EPS of $8.93, up 22.5% from $7.29 in fiscal 2025. Its EPS is expected to rise 10.9% year-over-year to $9.90 in fiscal 2027.
WST stock has outperformed the S&P 500 Index’s ($SPX) 15% gains over the past 52 weeks, with shares up 33.6% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 16.1% returns over the same time frame.
WST's outperformance was driven by its Proprietary Products portfolio, particularly high-value components for biologics and biosimilars. Growth was supported by strong participation in new biologic launches, rising demand for advanced containment solutions, and accelerated customer upgrades tied to stricter regulatory standards. GLP-1 therapies emerged as a key growth engine with broad-based demand, while operational excellence helped recover from a prior disruption and meet strong orders. The shift toward higher-value self-injection platforms and a favorable product mix is also supporting margin expansion.
Analysts’ consensus opinion on WST stock is bullish, with a “Strong Buy” rating overall. Out of 18 analysts covering the stock, 15 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and one gives a “Hold.” WST’s average analyst price target is $403.70, indicating a potential upside of 10.6% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.